Mc-Val-Cit-PABC-PNP: Protocol Guidance for Cathepsin Cleavable ADC Peptide Linkers

What This Product Solves

Antibody-drug conjugate (ADC) development demands precise control over payload release to minimize off-target effects and enhance therapeutic index in targeted drug delivery research. Mc-Val-Cit-PABC-PNP addresses this by functioning as a cathepsin B-cleavable peptide linker. Upon internalization of the ADC by target cells and trafficking to lysosomes, cathepsin proteases cleave the linker, triggering payload release. This design supports selective cytotoxicity and is particularly relevant in workflows aiming to recapitulate the mechanism found in FDA-approved ADCs, such as brentuximab vedotin. The linker’s solubility and chemical stability parameters make it suitable for organic-solvent workflows, while its susceptibility to lysosomal proteases underpins its utility in constructing ADCs with defined release kinetics.

Protocol Parameters

• Solubility in DMSO | ≥36.9 mg/mL | Use in organic-solvent based ADC conjugation protocols | Ensures efficient dissolution for coupling reactions; not water-compatible | product information
• Recommended Storage | -20°C (solid form) | Long-term solid storage for batch consistency | Maintains chemical stability and prevents degradation; avoid repeated freeze-thaw | product information
• Solution Handling | Prepare fresh; avoid long-term storage | Conjugation steps should use freshly dissolved linker | Solutions degrade over time at ambient or refrigerated conditions; immediate use maximizes integrity | product information
• Purity | 98.00% (supplied) | Suitable for research-grade ADC synthesis | High purity reduces risk of off-target conjugation or undesired by-products | product information

Workflow Setup and QC Checklist

When planning ADC synthesis with Mc-Val-Cit-PABC-PNP, follow the checklist below to ensure reproducibility and minimize common errors:

• Pre-dissolution: Confirm the linker’s mass using an analytical balance. Use anhydrous DMSO for dissolution, achieving concentrations suitable for your conjugation protocol (up to 36.9 mg/mL as per product data).
• Conjugation Buffer: Ensure the antibody and payload components are compatible with organic solvent conditions, as the linker is insoluble in water and ethanol. Avoid inclusion of aqueous buffers prior to complete linker dissolution.
• Reaction Monitoring: Use analytical HPLC or LC-MS to monitor conjugation efficiency and to detect hydrolysis or by-product formation.
• Post-conjugation QC: Assess final ADC purity and integrity by SDS-PAGE and functional assays targeting lysosomal cleavage (in vitro cathepsin B assay, if available).
• Storage: Store unused solid linker at -20°C in a desiccated environment. Discard any unused solutions; do not freeze or refrigerate dissolved linker for later use.

For further protocol details and workflow considerations, see the internal article "Mc-Val-Cit-PABC-PNP: Technical Guide for ADC Synthesis Workflows", which outlines setup and solubility constraints for organic-phase conjugations.

Common Failure Modes and Fixes

• Poor linker dissolution: If the linker does not fully dissolve, verify DMSO dryness and increase mixing time. Avoid water or ethanol as solvents, as the product is insoluble in these.
• Low conjugation efficiency: Ensure the linker is freshly dissolved and used immediately. Degraded linker from old solutions may lead to reduced coupling or incomplete payload release.
• Unintended hydrolysis or instability: Maintain all handling at low temperatures and minimize exposure to ambient humidity. Always prepare solutions immediately before use to avoid breakdown.
• Payload release outside lysosomes: If premature payload release is observed, verify that the conjugation protocol preserves the intact Val-Cit-PABC motif and that the resulting ADC is not exposed to proteases outside lysosomal conditions.

The article "Mc-Val-Cit-PABC-PNP: ADC Peptide Linker for Cathepsin Cleavage" provides additional troubleshooting steps for selective lysosomal release.

Scope and Limitations

Mc-Val-Cit-PABC-PNP is strictly intended for scientific research in antibody-drug conjugate synthesis and related targeted drug delivery research within organic-phase workflows. It is unsuitable for water-based, diagnostic, therapeutic, or in vivo use, as supported by product data and internal literature. The linker’s performance is optimal under organic solvent conditions and in protocols explicitly requiring cathepsin B substrate linker functionality for lysosomal cleavage. Researchers should not use this product for direct clinical or diagnostic investigations, nor in protocols demanding aqueous compatibility.

Product stability is limited to the solid form at -20°C. Dissolved solutions should be used promptly and not stored, as prolonged exposure or freeze-thaw can compromise chemical integrity and downstream conjugation efficiency.

Conclusion

Mc-Val-Cit-PABC-PNP offers a robust solution for constructing cathepsin cleavable ADC peptide linkers in research settings. By adhering to strict handling, storage, and workflow recommendations, researchers can utilize this linker to achieve reliable and selective payload release profiles that mimic clinically validated ADC designs. For full product specifications and order information, refer to Mc-Val-Cit-PABC-PNP at APExBIO.